In 1995, a new flavivirus called both hepatitis G virus (HGV) and GB virus C (GBV-C) was identified [1, 2] . So far no specific disease is associated with this virus and we will use the name GBV-C for the remainder of this article. In recent years, several studies have found that GBV-C-RNA detection in HIV-infected patients was associated with slower progression to AIDS, longer survival after the development of AIDS, and lower overall mortality [3] [4] [5] . Only three studies have estimated the prevalence of GBV-C in HIV-1-infected adults in developing countries [6] [7] [8] . All were carried out among pregnant women in Africa, and found GBV-C-RNA-positive prevalence rates ranging from 20 to 36%. There was no association between CD4 T-cell counts and the presence of GBV-C-RNA in the two studies that looked at the association [6, 8] . We report here our experience with GBV-C-RNA detection in a group of HIV-infected patients in Cambodia.
Since February 2003, HIV-infected patients seen at Calmette Hospital in Phnom Penh have access to HAART through a French-Cambodian interhospital collaborative programme called ESTHER. As part of the pretreatment evaluation, patients are screened for a variety of biological markers and viral co-infections. Patients with clinical AIDS [9] or with CD4 cell counts less than 200 cells/ml are eligible for HAART. Based on recent information regarding the protective effect of GBV-C on the progression of HIV infection [3, 4] , all baseline samples of patients participating in the ESTHER programme were tested for the presence of GBV-C-RNA.
GBV-C-RNA testing was done using nested reverse transcriptase-polymerase chain reaction (RT-PCR). GBV-C-RNA was extracted using the QiaAmp viral RNA kit (Qiagen SA, Courtaboeuf, France) and amplified using a nested RT-PCR focusing on the 5 0 non-coding region of the GBV-C viral genome with HGV untranslated region (UTR) 1s (5 0 -AgggTTSgTAggTSTAAATCCC-3 0 ) and HGV UTR2 (5 0 -TgCCACCMgSSSTCACCCgAAgg-3 0 ) as outer primers and HGV UTR3s (5 0 -TggBSMYWCCggTgTg AATAR-3 0 ) and HGV UTR4as (5 0 -SVSCTKgg TggCCCCRTg-3 0 ) as inner primers. The first PCR was combined with the RT step in the same tube as previously described [10] . Amplification reactions were carried out by using the following thermal cycles for the first and second rounds of amplification: 958C for 10 min followed by 30 cycles at 948C for 30 s, 508C for 30 s, 728C for 90 s and a final extension step of 7 min at 728C. PCR products were visualized after electrophoresis on 1.5% ethidium bromide-stained agarose gel and observed under ultraviolet light.
Quartiles were used to define lymphocyte count categories, whereas the definition of anaemia was a haemoglobin value of less than 13.5 g/dl for men and less than 12 g/dl for women [11] . Means and proportions were compared across study groups using the Mann-Whitney U test and chi-square test when appropriate. The Fisher's exact test was used for the comparison of categorical variables when more than 20% of cells had expected counts less than five. Multivariate analysis for factors associated with GBV-RNA detection was performed using logistic regression. P values less than 0.05 were considered statistically significant. All statistical analyses were performed using Stata statistical software (Stata 8; Stata Corp., College Station, Texas, USA).
Between February and September 2003, 213 patients were enrolled in the study. A total of 135 (63.4%) were men, and the median (range) age of the study group was 34 years (19-64). Although the source of infection was not known for most patients, only one (0.5%) acknowledged intravenous drug use. Most patients had advanced HIV infection, with only 34 patients (16.0%) having CD4 cell counts above 200 cells/ml. Clinical AIDS was present in 86 patients (40.4%). Hepatitis B surface antigen carriage was present in 31 of 210 patients (14.8%), and anti-hepatitis C virus (HCV) antibodies were present in 22 of 213 (10.3%).
GBV-C-RNA was detected in 35 of 213 patients (16.4%). The prevalence of GBV-C-RNA did not differ by sex, age group, or HBV/HCV co-infection status (Table 1) . However, it was lower among patients with a past/present history of tuberculosis, anaemia, low lymphocyte percentages, low CD4 cell counts, and the use of traditional medicine, compared with others. The proportion of patients with positive GBV-C-RNA decreased dramatically with CD4 cell counts less than 100 cells/ml, being 29.4, 28.8, 9.5, and 2.8% for CD4 cell counts of 200 or greater, 100-199, 50-99, and less than 50 cells/ml, respectively (P < 0.001). In multivariate analysis, a past/ present history of tuberculosis, anaemia, the use of traditional medicine, and low CD4 cell counts remained independently and negatively associated with GBV-C-RNA detection ( Table 1 ).
The prevalence of GBV-C-RNA in this population of HIV-infected individuals in Cambodia, 16.4%, was similar to that seen in other populations of HIV-infected individuals elsewhere in the world. No association was found between GBV-C-RNA detection and age, sex, HBV or HCV co-infection. As found in other studies [12] , GBV-C-RNA detection decreased with the CD4 cell count, and only 2.8% of those with CD4 cell counts less than 50 cells/ml had detectable GBV-C. The studies that failed to show a similar association included patients with relatively high CD4 cell counts, and an examination of Table 1 confirms that the detection of GBV-C-RNA becomes lower only among those with CD4 cell counts of less than 100 cells/ml. This may explain why the African studies comparing CD4 cell counts with GBV-C-RNA status did not find any association [6, 8] . In those studies, the HIV-infected subjects were pregnant women, a population known to have relatively preserved CD4 cell counts at the time of pregnancy. In the only study providing details of CD4 cell counts, the mean CD4 cell count was above 450 cells/ml [6] . We confirm here an association between GBV-RNA detection and low CD4 cell counts in a population of the developing world, presumably infected heterosexually, and with predominantly subtype E infections [13] . The association was also found, independently, of CD4 cell counts, with other markers of advanced HIV infection such as a past/present history of tuberculosis and anaemia. Whether GBV-C truly protects against the progression of HIV infection is still debated. The fact that in prospective studies, GBV-C-RNA loss, rather than GBV-C-RNA absence, is associated with a poorer prognosis [5, 14, 15] , suggests that GBV-C-RNA detection might only be a marker of elevated CD4 cell counts. A better understanding of the mechanisms by which GBV-C interacts with HIV would be useful to understand the full implications of these findings. Human papillomavirus (HPV) types are associated with squamous cell cancers. HIV infection is linked with a higher prevalence of anal HPV infection. It is important to assess whether HPV is present in other body parts involved in sexual practices to establish a cancer prevention program. A high prevalence of high-risk HPV types was present in the anus, penis and mouth (78, 36 and 30%, respectively) in a cohort of HIV-infected males (men who have sex with men and heterosexual), without evidence of pathology in these areas.
High prevalence of human papillomavirus infection
Human papillomavirus (HPV) infection is considered to be a sexually transmitted disease, and the risk of HPV infection is increased by certain sexual behaviours [1] . HPV plays a role in the pathogenesis of distinct squamous cell cancers: there is a strong and consistent association between high-risk HPV types and cervical [2] , anal [3] , penile [4, 5] , oropharyngeal [6, 7] and conjunctival [8] cancers. Some of these HPV-associated malignancies occur at increased rates in persons with HIV/AIDS [9] . Likewise, the incidence of anal cancer among HIVpositive men who have sex with men (MSM) has been estimated to be twice that of HIV-negative MSM [10, 11] , and HAART has not been associated with a reduced prevalence [11] .
Current data on the spread of HPV infection to the different body parts implicated in sexual practices in both MSM and heterosexual men are limited. A cross-sectional study was carried out to evaluate the prevalence of HPV infection in the anus, penis and mouth in this population.
Between April and September 2005, all HIV-positive men ! 18 years, who were consecutively interviewed in the outpatient HIV Clinical Unit, were asked to participate in the study. Those with a history of previous anal, penile or oral pathology, and non-acceptance to participate in the study were excluded. The ethical committee approved the protocol and written consent was obtained.
All participants underwent high-resolution anoscopy and direct visual examination of the penis and mouth. Using a cytobrush, samples for HPV-DNA analysis from the anus (anal canal), penis (coronal sulcus, glands and urethra distal), and mouth (oral cavity, and oral rinse sample) were obtained. The sample from the anus was used to carry out a cytological analysis (Thin-Prep, Biomerieux, France). A blood sample was extracted for CD4 cell determination by flow cytometry and HIV-1 plasma viral load (Nuclisens, Cytyc UK, UK; detection limit, 50 copies/ml).
Polymerase chain reaction (PCR) as described previously [12] was used for assessing the presence of HPV-DNA (positive or negative) and different high oncogenetic risk (16, 18 , 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and low oncogenetic risk (6, 11) HPV genotypes.
Behavioural data were collected with a questionnaire distributed by a person who was not the participant's primary caregiver. The questionnaire collected detailed information regarding patients' sexual history, sexual preferences (heterosexual, homosexual or bisexual), drug and tobacco use, sexually transmitted diseases, HIV infection, and anal-penile-oral pathologies.
A descriptive analysis of HPV infection and exploratory analyses (univariate and multivariate) of the potential risk factors were performed.
The study included 74 men: 52 MSM (12 of them bisexual) and 22 heterosexuals. The mean age was 42 years (SD ¼ 8.7), 74% were taking HAART, 72% had a HIV viral load < 50 copies/ml and the mean CD4 cell count was 509 cells/ml (SD ¼ 265).
The overall prevalence of anal HPV infection in HIVpositive men was 78% [95% confidence interval (CI), 67-87%], with a prevalence of 83% (95% CI, 70-92%) in MSM and 68% (95% CI, 45-86%) in heterosexual men, P ¼ 0.22. The median number of different HPV types in the anus of HPV-infected patients was 3 [interquartile range (IQR), [1] [2] [3] [4] , and the most widespread HPV types were 16 and 33 (Table 1) The overall prevalence of concomitant HPV infection in two or three different body parts involved in sexual practices was 46% (95% CI, 34-58%), with a prevalence of 48% (95% CI, 34-62%) in MSM and 41% (95% CI, 21-64%) in heterosexual men.
This study is distinct from previous research because it screened for the presence of HPV infection in the different body parts involved in sexual practices in the same patient (including MSM and heterosexuals). We have found in MSM and heterosexual HIV-infected patients a high prevalence of HPV infection simultaneously at different levels (anus, penis, mouth), in the same individual. Indeed, our results confirmed the high prevalence reported previously of anal [13] and oral [14] high-risk HPV infection in HIV-positive men. In addition, 62% had an anal HPV infection despite having normal anal cytology. Due to the well established association between HPV infection and squamous cell cancers, our findings support the need for a close follow up in all HIV/HPV co-infected patients in order to detect early cancer changes in the anus, penis and mouth. The fact that a slightly increased trend has been observed [9] might be related to the significant post HAART increase in life expectancy. Interestingly, the rate of high-risk penile HPV infection may account for the spread of the disease and forces all co-infected patients to use condoms, even for oral sex. According to these results, the upcoming first generation HPV vaccines (solely covering HPV-16 and 18) would have been useful for preventing only 43% of the anal cancer cases in the patients we have studied.
Our findings suggest that the presence of HPV infection in the anus, penis and mouth should be determined in any HIV-infected male patient. In the event that a high-risk HPV infection is detected, monitoring with diagnostic procedures for squamous cell cancers is recommended.
'Serosorting' in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia This paper addresses the question of whether HIVnegative gay men engage in 'serosorting' in casual encounters. Serosorting, defined as engaging in unprotected anal intercourse with casual partners who they report to be HIV negative, has been increasing among HIV-negative gay men in Sydney. Prevention and intervention programmes are urgently needed to alert HIV-negative gay men to the risks associated with 'serosorting', and remind them of the need for consistent condom use.
The practice of 'serosorting' by men who have sex with men (MSM) was defined by Suarez and colleagues [1, 2] as 'discussing HIV status with potential partners and only engaging in risk behaviour with those they believe are of a similar serostatus' [2] . HIV-positive MSM have been reported to engage in unprotected anal intercourse (UAI) with either steady (regular) or casual seroconcordant partners ('positive-positive' sex) [3] [4] [5] [6] [7] [8] [9] . Very few studies, however, have provided data on serosorting among HIVnegative MSM. One US study suggested that men who believed they were HIV negative could be increasingly avoiding HIV-positive sex partners [10] .
In this paper we provide data on 'serosorting' in casual encounters from a cohort of confirmed HIV-negative gay men in Sydney [11] . Participants were not asked whether they actually engaged in serosorting. In the whole cohort, there was a decrease in the mean number of total UAIC partners in the 6 months before interview (RR per year 0.92, 95% CI 0.90-0.94, P < 0.001). However, when stratified by partner's HIV serostatus, there was an increase in the mean number of UAIC partners reported to be HIV negative (RR 1.11, 95% CI 1.05-1.17, P < 0.001). This corresponded to an increase in the proportion of HIV-negative UAIC partners: from 12.3% in 2002 to 24.3% in 2005 (Table 1) .
To verify that results from the whole cohort were not merely caused by a possible change in cohort composition, we then selected men who had completed all four interviews from 2002 to 2005 (N ¼ 302). The pattern from the subsample was matched with that from the whole sample. There was a decrease in the mean number of total UAIC partners over the 4-year period (RR 0.89, 95% CI 0.86-0.92, P < 0.001) but a significant increase in the mean number of UAIC partners reported to be HIV negative (RR 1.31, 95% CI 1.19-1.45, P < 0.001).
The proportion of HIV-negative UAIC partners increased from 6.4% in 2002 to 24.6% in 2005 (Table 1 ).
In general, we found a significant increase over time in apparent 'serosorting' in casual encounters among HIVnegative gay men in Sydney, where HIV testing rates are high and stable. Although the majority of UAIC (over 60%) still occurred with partners of an unknown HIV status, our results show that in 2005, 'serosorting' accounted for nearly one-quarter of all reported UAIC. This was even more pronounced against the background of a decrease in the total number of UAIC partners over time. More studies are needed to explore the meaning of UAIC within the context of negative seroconcordancy in different populations of MSM.
There are a number of limitations to our findings. We did not ask whether participants interpreted their practice as serosorting, rather evidence of 'serosorting' was inferred from information provided by respondents about their UAIC partners. Furthermore, our findings may be limited to men who have annual or frequent HIV tests, but this applies to the great majority of gay men in Australia.
For men who have not been diagnosed as HIV positive, 'serosorting' is based on the assumed serostatus of both self and casual partners. Such a practice, especially if used as a deliberate strategy to replace consistent condom use with casual partners, is highly problematical. First, even if both partners are, indeed, HIV-negative, unprotected anal intercourse still carries risks of other sexually transmitted infections, which can facilitate HIV transmission [12] . Second, the assumed HIV-negative status of self or of casual partners does not necessarily correspond with the actual HIV status as seroconversion may have occurred since the last HIV test. This particularly pertains to countries in which the level of HIV testing is low, regular HIV testing has not yet been widely adopted, or HIV incidence is high. Third, assuming that all casual sex partners will honestly disclose their HIV status is unrealistic. Serosorting in casual encounters is not the same as 'negotiated safety' [2, 13] . Finally, the exchange of information about each other's assumed HIV status is often not practised through direct face-to-face verbal discussion but rather is implied or inferred from nonverbal cues [1, 2, 14] , making it even more problematical than when such a discussion does occur. In this context, the perception of a casual partner's HIV status may also be related to certain degrees of familiarity between them.
Future research should investigate reasons for the increase in 'serosorting' among HIV-negative MSM, including the role of the Internet, as serosorting can be easily facilitated through the Internet [9, [15] [16] [17] . Whether online HIV status disclosure is the main reason for this increase is worthy of examination.
Policy makers, educators and researchers in the HIV prevention field should be alerted to this phenomenon of HIV-negative 'serosorting' in casual sex, and investigate whether this is indeed a new trend. They need to address this issue in prevention messages to make gay and bisexual men aware of the risks of HIV-negative serosorting with casual partners. One way forward may be to ensure that education and prevention materials differentiate clearly the consequences of serosorting among HIV-positive men from those among HIV-negative men. Based on very small numbers of men who engaged in UAIC with a partner reported to be HIV positive in the previous 6 months before the survey. 
